Compare · KLRA vs NVO
KLRA vs NVO
Side-by-side comparison of Kailera Therapeutics Inc. (KLRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KLRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 71.8x KLRA ($2.55B).
- Over the past year, KLRA is down 24.8% and NVO is down 45.7% - KLRA leads by 20.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for KLRA).
- NVO has more recent analyst coverage (25 ratings vs 6 for KLRA).
- Company
- Kailera Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $19.68+1.44%
- $41.01-4.51%
- Market cap
- $2.55B
- $183.15B
- 1M return
- -12.46%
- -10.44%
- 1Y return
- -24.76%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 5
- 8
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KLRA
- Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
- Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- SEC Form 10-Q filed by Kailera Therapeutics Inc.
- Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
- Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
- Analyst initiated coverage on Kailera Therapeutics with a new price target
- William Blair initiated coverage on Kailera Therapeutics
- Leerink Partners initiated coverage on Kailera Therapeutics with a new price target
- TD Cowen initiated coverage on Kailera Therapeutics with a new price target
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care